Previous Close | 20.42 |
Open | 20.26 |
Bid | 20.19 x 300 |
Ask | 20.34 x 200 |
Day's Range | 20.02 - 20.68 |
52 Week Range | 12.32 - 32.10 |
Volume | |
Avg. Volume | 680,721 |
Market Cap | 877.457M |
Beta (5Y Monthly) | -0.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.32 |
Earnings Date | Apr 29, 2024 - May 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Dec 13, 2012 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for SAVA
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced th
Quite a few insiders have dramatically grown their holdings in Cassava Sciences, Inc. ( NASDAQ:SAVA ) over the past 12...
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024. Presentation details Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 T